Core Insights - Curaleaf Holdings, Inc. anticipates Q4 2025 net revenue to be at least $330 million, reflecting a sequential increase of approximately 4% and a year-over-year increase of 1% compared to Q4 2024 [1] - The company plans to discontinue its hemp business and exit Missouri due to new federal regulations, which combined contributed approximately $2 million in revenue in Q3 and Q4 2025 [1] - Adjusted gross profit margin for Q4 2025 is expected to be around 48.5%, consistent with Q4 2024, while the full year 2025 adjusted gross margin is projected to be approximately 50% [1] Financial Performance - Q4 2025 net revenue, excluding discontinued businesses, is expected to be at least $330 million, surpassing previous guidance of low single-digit growth [1] - The anticipated adjusted gross profit margin for Q4 2025 is approximately 48.5%, aligning with the previous year's margin [1] - Full year 2025 adjusted gross margin is expected to be around 50% [1] Strategic Decisions - The decision to discontinue the hemp division is a response to federal legislation that limits THC levels in hemp-derived products [1] - The exit from Missouri is based on the assessment that the company's presence in the state was not justifiable for continued investment [1] - The company aims to maintain a robust balance sheet while refinancing senior secured notes due in December 2026 [1]

Core Insights - Glass House Brands Inc. is accelerating its expansion plans for 2026 due to positive results from previous developments and anticipated cannabis reform actions [1][8] Production Capacity - The company has returned to full production capacity in its existing greenhouses and completed the buildout of the first third of Greenhouse 2, marking the highest planted acreage in its history [2] - Greenhouse 2 will add approximately 300,000 lbs. of biomass in annual production capacity, with full planting expected by the second quarter of 2026 [3] New Developments - A light retrofit and buildout of Greenhouse 4 has commenced, targeting international CBD and hemp markets, with plans to supply the reimbursable CBD market under President Trump's Executive Order [4][6] - The company is preparing for new business opportunities arising from cannabis rescheduling and the creation of a Medicare reimbursement program for CBD [6] Market Position - Glass House is positioned to capitalize on growth opportunities in the U.S. CBD market, with existing CBD/low THC strains that can comply with new federal regulations [6] - The company is engaged in developing medicinal cannabinoids through a partnership with the University of California Berkeley, aiming to be a leading supplier in pharmaceutical and consumer packaged goods markets [6] Expansion Strategy - The company is accelerating its expansion efforts by planning production in two additional greenhouses and targeting markets outside of California [8] - The expansion is driven by confidence in restoring existing operations and developing new business opportunities, including international exports [8]

Core Insights - Aurora Cannabis Inc. has been granted community plant variety rights by the EU for two proprietary cannabis varieties, enhancing its leadership in cannabis genetics and reinforcing its commitment to innovation [1][3] Group 1: Intellectual Property and Innovation - The granted plant variety rights pertain to two Cannabis sativa L varieties named SOT20R07-007 (Farm Gas) and ACB21T044 (Sourdough), which are recognized for their high potency, desirable aromas, and strong performance traits [2][3] - This achievement strengthens Aurora's global genetics portfolio and allows for exclusive control over the commercial production and sale of these varieties across the EU's 27 member states [3][4] Group 2: Market Position and Product Offering - Aurora's cultivars are available to medical patients in multiple countries, including Germany, Poland, the UK, Canada, and Australia, showcasing the company's international reach [2] - The protection of these varieties enhances Aurora's competitive position in Europe, a key market for the company [4] Group 3: Commitment to Quality - The company emphasizes its dedication to advancing its breeding program and developing genetics that set new standards in cannabis cultivation [3] - Aurora's robust genetics platform supports its ability to deliver consistent, reliable, and premium products to the market [4]

Core Viewpoint - Tilray Brands is showing signs of recovery after a significant decline in market value over the past five years, with recent positive momentum attributed to regulatory changes and a favorable quarterly update [1][2]. Financial Performance - Tilray reported a record revenue of $218 million for the second quarter of fiscal year 2026, exceeding analyst expectations, although year-over-year growth was only 3% [3]. - The company's gross margin decreased to 26% from 29%, but it reported a narrower net loss of $43.5 million compared to a loss of $85.3 million in the same quarter last year [4]. Regulatory Developments - Positive regulatory changes in the U.S. cannabis market, including the reclassification of cannabis as a Schedule 3 substance, are expected to provide significant opportunities for Tilray [4][6]. - The reclassification allows for easier access to financial services, more medical research into marijuana, and the ability to deduct normal business expenses [6]. Market Expansion - Following the regulatory changes, Tilray is expanding its medical cannabis operations in the U.S. through the launch of Tilray Medical USA, aiming to broaden its portfolio and reach more patients [7].

Core Insights - The article highlights Alan Brochstein's extensive experience in the investment industry, particularly his focus on the cannabis sector since 2014 [1] - It emphasizes the importance of ETFs in enabling diversified investment portfolios for both individual and institutional investors [1] - The article mentions Brochstein's efforts to educate investors about the ETF landscape and the associated risks [1] Group 1: Professional Background - Alan Brochstein has been contributing to Seeking Alpha since 2007 and has a background in both sell-side and buy-side roles in fixed-income and equities [1] - He founded AB Analytical Services in 2007 to provide independent consulting to registered investment advisors [1] - Brochstein launched 420 Investor in 2013, focusing on cannabis stocks, and has been a significant figure in the cannabis investment space since then [1] Group 2: ETF Focus - Brochstein has been writing extensively about ETFs since 2025, aiming to help investors understand the ETF universe [1] - He maintains a 79-ETF Focus List that includes both popular and lesser-known ETFs that he believes stand out [1] - A model portfolio was created by Brochstein as of year-end 2025 to assist investors in navigating their ETF investments [1]

Core Insights - President Trump's executive order to reschedule cannabis to Schedule 3 is considered a significant shift in federal cannabis policy, potentially alleviating the burdensome tax regime affecting U.S. cannabis operators for decades [1][2]. Tax Implications - The executive order could lead to the elimination of Section 280E of the Internal Revenue Code, which currently taxes legal cannabis operators as if they were narcotics traffickers, preventing them from deducting any business expenses [2][3]. - Rescheduling cannabis to Schedule 3 would allow U.S. companies to deduct standard operating costs, significantly improving their financial health and cash flow [3]. Market Reaction - The cannabis industry is responding positively to the news, especially after a strong performance in 2025, where the AdvisorShares MSOS ETF outperformed the S&P 500 [4]. - Despite the optimistic outlook, the sector is still viewed as highly volatile, with many institutional investors remaining cautious due to past political inaction [4]. Remaining Challenges - Even with the potential rescheduling, U.S. cannabis companies still face hurdles, such as the inability to list on major exchanges like NASDAQ or NYSE, which is available to Canadian companies [5]. - The industry is also awaiting "safe harbor" provisions for banking, which remain unresolved [5]. Stock Performance - Recent performance data for cannabis stocks and ETFs shows varied results, with AdvisorShares Pure U.S. Cannabis ETF (NYSE:MSOS) leading with a 68.55% increase over six months, while other companies like Tilray Brands Inc. (NASDAQ:TLRY) and Canopy Growth Corp. (NASDAQ:CGC) show mixed performance [7].

Core Insights - Simply Solventless Concentrates Ltd. (SSC) is enhancing its cultivation facility through a retrofit by its subsidiary Humble Grow Co., which is expected to significantly increase revenue and EBITDA [2][6]. Humble Retrofit - The retrofit involves the installation of LED lights and other improvements, with a total capital cost of approximately $2.5 million, netting to $1.5 million after government rebates [2]. - Once the retrofit is fully operational by early Q3 2026, SSC anticipates an increase in annual gross revenue by $17.5 million to $29.5 million, resulting in total revenue projections of $53.5 million to $65.5 million [2][3]. - The adjusted EBITDA is expected to rise by $6.5 million to $14.5 million, reaching a range of $10.7 million to $18.7 million [2][5]. Market Expansion - SSC plans to maintain a balanced sales mix of 50% B2B and 50% CPG (consumer packaged goods) post-retrofit, targeting both domestic and international markets [3][7]. - The company has set pricing for saleable cannabis flower at $3.00 per gram for CPG, $1.60 for Canadian B2B, and $1.90 for international B2B [7]. Acquisition Integration & Cost Savings - SSC has completed four acquisitions over the past 18 months, achieving significant cost savings, including a reduction in headcount by 45% and payroll costs by 44%, amounting to $7.8 million annually [6][8]. - The integration of these acquisitions is substantially complete as of December 2025, contributing to operational efficiencies [6]. Financial Projections - The company’s financial projections indicate a corporate growth of 49% to 82% in gross revenue and a growth of 155% to 345% in adjusted EBITDA post-retrofit [5][6]. - The annualized adjusted EBITDA per share is projected to increase from $0.09 to $0.16 depending on the case scenario [5].

Quick Read AdvisorShares Pure US Cannabis ETF (MSOS) dropped 26% to $4.80 by mid-January despite Trump’s December executive order. MSOS holds $921M and gains exposure to Curaleaf and Trulieve through swap contracts and direct equity positions. Curaleaf and Trulieve face 280E tax penalties and banking restrictions while cannabis remains a Schedule I substance. A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more ...

Core Insights - The sin stock market consists of companies in sectors considered unethical or socially undesirable, including alcohol, tobacco, gambling, weapons, and cannabis [1] - Sin stocks are often excluded by institutional and ESG-focused investors, leading to lower valuations and higher dividend yields, which can present opportunities for return-focused investors [2] Investment Characteristics - Sin stocks generate stable cash flows due to consistent demand, making them attractive for investors seeking defensive exposure [3] - These companies often trade at lower valuation multiples compared to the broader market, while strong cash generation allows for above-average dividend yields [4] - Sin stock companies can pass on cost increases through price hikes due to high barriers to entry, protecting margins and supporting long-term profitability [5] - Sin stocks exhibit low correlation with economic cycles, providing useful portfolio diversification [6] Investor Mindset - Investors in sin stocks prioritize risk-adjusted returns, income stability, and diversification, weighing ethical concerns against financial objectives [7] Sector Trends - Alcohol companies like Diageo benefit from premiumization and steady global demand, while tobacco firms like Philip Morris are transitioning to reduced-risk products [9] - Gambling stocks are experiencing growth from online betting and digital gaming legalization, while weapons stocks are influenced by geopolitical tensions [10] Company Highlights - Boyd Gaming's appeal lies in its diversified gaming portfolio and disciplined capital allocation, with a focus on operational efficiency and customer loyalty [12] - Universal Corporation reported 3% revenue growth and an 18% increase in operating income in the first half of fiscal 2026, supported by strong demand dynamics [14] - Constellation Brands maintains a dominant position in the U.S. high-end beer market, with strategies that emphasize pricing discipline and cost-saving initiatives [16]

Core Viewpoint - Rubicon Organics Inc. is a leading premium licensed producer of organic cannabis in Canada, announcing the grant of 1,002,773 restricted share units (RSUs) and 1,002,773 performance share units (PSUs) to its executives and employees [1] RSU Grant - The company has awarded a total of 1,002,773 RSUs under its Omnibus Equity Incentive Plan, which will vest over one to three years from the grant date, allowing holders to receive one common share or cash at the Board's discretion [2] PSU Grant - A total of 1,002,773 PSUs have been granted, which will vest after three years based on the achievement of specific performance targets, with each vested PSU entitling the holder to one common share or cash at the Board's discretion [3] Company Overview - Rubicon Organics is recognized as the Canadian leader in certified organic and premium cannabis, operating a vertically integrated model with a strong national distribution network [4] - The company's production capabilities are anchored by its Pacifica facility in Delta, BC, and the newly acquired Cascadia facility in Hope, BC, which will increase production capacity by over 40% [5] Market Position and Growth Potential - As the Canadian cannabis market rationalizes and global demand for high-quality cannabis rises, Rubicon Organics distinguishes itself through disciplined execution, brand equity, and consumer loyalty [6] - The company's focus on premium quality, innovation, and operational execution has led to consistent revenue growth and positive Adjusted EBITDA, positioning it for long-term growth potential [6]